Related Experiment Video
Updated: Aug 11, 2026
07:49
Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions
Published on: September 17, 2014
Multiple-dose pharmacokinetic study with a slow-release carbamazepine preparation
M Reunanen1, E Heinonen, M Anttila
1Department of Neurology, University of Oulu, Finland.
Epilepsy Research
|July 1, 1990
Summary
Slow-release carbamazepine (CBZ) provides more stable serum concentrations and fewer seizures than conventional formulations. This improved stability with slow-release CBZ reduces side effects like dizziness, enhancing patient outcomes.
Area of Science:
- Pharmacology
- Clinical Pharmacy
- Neurology
Background:
- Carbamazepine (CBZ) is a widely used antiepileptic drug.
- Optimizing CBZ delivery is crucial for managing epilepsy and minimizing side effects.
- Steady-state pharmacokinetics and clinical outcomes of different CBZ formulations require investigation.
Purpose of the Study:
- To compare the pharmacokinetics, clinical efficacy, and side effects of a slow-release (SR) CBZ preparation (Neurotol Slow) versus a conventional (C) preparation (Tegretol).
- To evaluate CBZ and its metabolite carbamazepine-10,11-epoxide (CBZE) serum concentrations, seizure frequency, and adverse events in epileptic patients.
Main Methods:
- A single-blind, randomized cross-over study involving 18 adult epileptic patients on stable CBZ doses.
- Blood samples were collected over 12 hours post-dose to measure serum CBZ and CBZE concentrations using HPLC.
- Seizure counts and side effects were recorded during two 2-week treatment periods for each formulation.
Main Results:
- SR formulation resulted in significantly lower peak CBZ and CBZE concentrations and a longer time to reach peak levels.
- Serum CBZ and CBZE fluctuations were significantly reduced with SR treatment.
- Bioavailability did not differ significantly between SR and C preparations.
- Epileptic seizure frequency was lower with SR (31 seizures) compared to C (57 seizures).
- Side effects, particularly dizziness, were significantly less common with SR treatment.
Conclusions:
- Slow-release carbamazepine (SR CBZ) offers improved pharmacokinetic stability compared to conventional formulations.
- SR CBZ demonstrates enhanced clinical efficacy by reducing seizure frequency.
- The use of SR CBZ formulations can lead to a better side effect profile, improving patient tolerability and adherence.
Related Concept Videos
01:11Bioavailability Study Design: Single Versus Multiple Dose Studies
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
01:21Drug Accumulation During Multiple Dosing: Repetitive IV Injections
Calculating drug dosage and accumulation in multiple-dose regimens is crucial for achieving therapeutic efficacy while avoiding toxicity. This involves determining the plasma drug concentrations over time to optimize dosing schedules. The principle of superposition is fundamental in this process, allowing for the prediction of drug concentration in plasma following multiple doses based on single-dose data.The principle of superposition asserts that the plasma concentration-time curves from...
01:24Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
01:22Modified-Release Drug Delivery Systems: Drug Release Characteristics
Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
01:26Oral Drug Delivery Systems: Continuous-Release Systems
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...